作者:Rui Ding、Ting Zhang、Daniel J. Wilson、Jiashu Xie、Jessica Williams、Yue Xu、Yihong Ye、Liqiang Chen
DOI:10.1021/acs.jmedchem.9b00144
日期:2019.3.14
Inhibitors of human p97 (also known as valosin-containing protein) have been actively pursued because of their potential therapeutic applications in cancer and other diseases. However, covalent and irreversible p97 inhibitors have not been well explored. Herein, we report our design, synthesis, and biological evaluation of covalent and irreversibleinhibitors of p97. Among an amide and a reverse amide
Gold(III)-Catalyzed 1,4-Nucleophilic Addition: Facile Approach to Prepare 2-Amino-1,4-naphthalenedione and 6-Amino-5,8-quinolinedione Derivatives
作者:Shaozhong Wang、Chunhui Jiang
DOI:10.1055/s-0028-1088116
日期:2009.4
An efficient approach is developed to prepare different 2-amino-1,4-naphthalenedione and 6-amino-5,8-quinolinedione derivatives regioselectively by Au(III)-catalyzed 1,4-nucleophilic addition and subsequent oxidation. A wide variety of primary, secondary, and aromatic amines, as well as allylamine and 2-butynylamine are well tolerated under the mild conditions to give products in moderate to good yields.
Intramolecular Inverse Electron-Demand [4 + 2] Cycloadditions of Ynamides with Pyrimidines: Scope and Density Functional Theory Insights
作者:Guillaume Duret、Robert Quinlan、Boyang Yin、Rainer E. Martin、Philippe Bisseret、Markus Neuburger、Vincent Gandon、Nicolas Blanchard
DOI:10.1021/acs.joc.6b02986
日期:2017.2.3
prepared in only three steps from commercially available pyrimidines. The key step of this short sequence is a [4 + 2]/retro-[4 + 2] cycloaddition between a pyrimidine and an ynamide, which constitutes the first examples of ynamides behaving as electron-rich dienophiles in [4 + 2] cycloaddition reactions. In addition, running the ihDA/rDA reaction in continuous mode in superheated toluene, to overcome
[EN] 8 - SULFO - IMIDAZOTETRAZIN- 4 - ONE COMPOUNDS AND THEIR USE AS ANTICANCER DRUG<br/>[FR] COMPOSÉS 8-SULFO-IMIDAZOTÉTRAZIN-4-ONE ET LEUR UTILISATION EN TANT QUE MÉDICAMENT ANTICANCÉREUX
申请人:PHARMINOX LTD
公开号:WO2012085501A1
公开(公告)日:2012-06-28
Compounds of formula (I) and pharmaceutically acceptable salts, hydrates or solvates thereof are provided (I) wherein B, X, and Y are as defined herein. The compounds are of use in methods of regulating cell proliferation, inhibiting cell cycle progression, and/or promoting apoptosis, and in the treatment of proliferative disorders.
Natural products have long been important inspirations for the development of chemical methodologies, theories, and technologies, and ultimately, discoveries of new drugs and materials. Chemical syntheses have traditionally yielded individual or small groups of natural products; however, methodology development allowing the synthesis of a large collection of natural products remains scarce. Here, we